Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Corticosteroid Therapy of Septic Shock - Corticus
This study has been completed.
Sponsors and Collaborators: Hadassah Medical Organization
European Society of Intensive Care Medicine
International Sepsis Forum
The Gorham Foundation
Information provided by: Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00147004
  Purpose

The purpose of the study is to determine whether steroids decrease 28-day mortality in patients with septic shock.


Condition Intervention Phase
Shock, Septic
Drug: hydrocortisone sodium succinate
Drug: Placebo
Phase III

Drug Information available for: Hydrocortisone Cortisol 21-phosphate Cortisol succinate Hydrocortamate Hydrocortisone 21-sodium succinate Hydrocortisone acetate Hydrocortisone cypionate Hydrocortisone hemisuccinate Proctofoam-HC Succinic acid Corticosteroids Epinephrine Epinephrine bitartrate
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Corticosteroid Therapy of Septic Shock - Corticus. A Multi-National, Prospective, Double-Blind, Randomized, Placebo-Controlled Study

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • 28 day mortality in all the non-responders to ACTH (< or = 9 mcg/dl or 250 nmol/L post ACTH) [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • 28 day all cause mortality in the total group. [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
  • 28 day all cause mortality in responders. [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
  • One year mortality in nonresponders, total and responders. [ Time Frame: one year ] [ Designated as safety issue: Yes ]
  • ICU and hospital mortality. [ Time Frame: one year ] [ Designated as safety issue: Yes ]
  • Organ system failure reversal, especially shock. [ Time Frame: one year ] [ Designated as safety issue: Yes ]
  • Duration of ICU and total hospitalisation. [ Time Frame: one year ] [ Designated as safety issue: Yes ]

Enrollment: 500
Study Start Date: March 2002
Study Completion Date: November 2005
Primary Completion Date: November 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
hydrocortisone sodium succinate
Drug: hydrocortisone sodium succinate
50 mg intravenous bolus every six hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and then stopped
2: Placebo Comparator
Placebo
Drug: Placebo

Detailed Description:

The use of steroids in septic shock remains controversial. The purpose of this study is to determine whether hydrocortisone decreases 28-day mortality in patients with septic shock. The primary end point will be 28-day mortality in all the non-responders to ACTH (< or = 9 mcg/dl or 250 nmol/L post ACTH). Secondary endpoints will be 28 day all cause mortality in the total group and in responders, ICU and hospital mortality, one year mortality, organ system failure reversal especially shock, and duration of ICU and total hospitalisation.

In a double-blinded fashion (randomized on a 1:1 basis), patients receive 50 mg intravenously every 6 hours for 5 days. After 5 days, treatment will be tapered with 50 mg given intravenously every 12 hours for days 6-8, then 50 mg every 24 hours for days 9-11, and then stopped.

All concomitant treatments, including antibiotics, fluids, vasopressors and ancillary therapies will be given at the discretion of the primary care physician. Evidence-based guidelines for the management of severe sepsis and septic shock by the International Sepsis Forum (Intensive Care Med 2001;27:S124-S134) are encouraged to be followed.

All serious adverse events (SAE) which occur between days 0 and 28, which are unexpected and/or considered possibly or probably related to the study medication, must be documented and reported within 24 hours to the Safety and Efficacy Monitoring Committee. Non-serious adverse events will be listed on the case report form if they are unexpected and believed to be related to the study drug during days 0 to 14.

Specific adverse events which will be monitored closely because of their relationship to corticosteroids and shock are:

  1. Use of corticosteroids, i.e. gastrointestinal bleeding and superinfection; hyperglycemia, hypernatremia, muscular weakness, etc.
  2. Shock and use of vasopressors, i.e. stroke, acute myocardial infarction and peripheral ischemia.

In addition, substudies will include harmonization of cortisol by comparing cortisol levels measured in local laboratories and a central laboratory, immune and neuro-endocrine interactions, neuromuscular weakness and cytokines.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Clinical evidence of infection within the previous 72 hours (may be present longer than 72 hours) (a, b, c, or d - only 1 required)

    1. Presence of polymorphonuclear cells in a normally sterile body fluid (excluding blood);
    2. Culture or Gram stain of blood, sputum, urine or normally sterile body fluid positive for a pathogenic micro-organism;
    3. Focus of infection identified by visual inspection (e.g. ruptured bowel with the presence of free air or bowel contents in the abdomen found at the time of surgery, wound with purulent drainage);
    4. Other clinical evidence of infection - treated community acquired pneumonia, purpura fulminans, necrotising fascitis, etc.
  2. Evidence of a systemic response to infection as defined by the presence of two or more of the following signs within the previous 24 hours. These signs may be present longer than 72 hours.

    1. Fever (temperature >38.3°C) or hypothermia (rectal temperature < 35.6°C);
    2. Tachycardia (heart rate of >90 beat/min);
    3. Tachypnea (respiratory rate > 20 breaths/min, PaC02<32 mmHg) or patient requires invasive mechanical ventilation;
    4. Alteration of the WBC count >12,000 cells/mm3, <4,000 cells/mm3 or >10% immature neutrophils (bands).
  3. Evidence of shock defined by (A + B- both required within the previous 72 hours (may NOT be present longer than 72 hours).

A. A systolic blood pressure < 90 mmHg or a decrease in SBP of more than 50 mmHg from baseline in previous hypertensive patients (for at least one hour) despite adequate fluid replacement OR need for vasopressors for at least one hour (infusion of dopamine ≥ 5 mcg/kg/min or any dose of adrenaline, noradrenaline, phenylephrine or vasopressin) to maintain a SBP ≥ 90 mmHg;

B. Hypoperfusion or organ dysfunction which is not the result of underlying diseases or drugs, but is attributable to sepsis, including one of the following:

  1. Sustained oliguria (urine output < 0.5 ml/kg/hr for a minimum of 1 hour)
  2. Metabolic acidosis [pH of < 7.3, or a base deficit of > or = 5.0 mmol/L, or an increased lactic acid concentration (> 2 mmol/L)].
  3. Arterial hypoxemia (Pa02/FI02<280 in the absence of pneumonia)(Pa02/FI02<200 in the presence of pneumonia).
  4. Thrombocytopenia - platelet count ≤ 100,000 cells/mm3.
  5. Acute altered mental status (Glasgow Coma Scale < 14 or acute change from baseline).

4. Informed Consent

5. Cortisol level at baseline and 60 minutes after 0.25 mg cosyntropin

Exclusion Criteria:

  1. Pregnancy
  2. Age less than 18.
  3. Underlying disease with a prognosis for survival of less than 3 months.
  4. Cardiopulmonary resuscitation within 72 hours before study.
  5. Drug-induced immunosuppression, including chemotherapy or radiation therapy within 4 weeks before the study.
  6. Administration of chronic corticosteroids in the last 6 months or acute steroid therapy (any dose) within 4 weeks (including inhaled steroids). Topical steroids are not exclusions.
  7. HIV positivity.
  8. Presence of an advanced directive to withhold or withdraw life sustaining treatment (i.e. DNR).
  9. Advanced cancer with a life expectancy less than 3 months.
  10. Acute myocardial infarction or pulmonary embolus.
  11. Another experimental drug study within the last 30 days.
  12. Moribund patients likely to die within 24 hours.
  13. Patients in the ICU for more than 2 months at the time of the start of septic shock.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00147004

  Show 57 Study Locations
Sponsors and Collaborators
Hadassah Medical Organization
European Society of Intensive Care Medicine
International Sepsis Forum
The Gorham Foundation
Investigators
Study Chair: Charles L Sprung, MD Hadasah Medical Organization
Study Director: Djillali Annane, MD Hopital Raymond Poincare
Study Director: Josef Briegel, MD Ludwig-Maximilian-Universitaet Muenchen
Study Director: Didier Keh, MD Charite Campus Virchow-Klinikum
Study Director: Rui Moreno, MD Hospital de St. António dos Capuchos
Study Director: Didier Pittet, MD Geneva University Hospitals
Study Director: Mervyn Singer, MD University College, London
  More Information

Publications of Results:
Other Publications:
Responsible Party: Hadassah Medical Organization ( Prof. Charles Sprung )
Study ID Numbers: QLK2-CT-2000-00589, EC- QLK2-CT-2000-00589
Study First Received: September 6, 2005
Last Updated: April 23, 2008
ClinicalTrials.gov Identifier: NCT00147004  
Health Authority: Austria: Federal Ministry for Health and Women;   Belgium: Directorate general for the protection of Public health: Medicines;   France: Afssaps - French Health Products Safety Agency;   Germany: Federal Institute for Drugs and Medical Devices;   Israel: Israeli Health Ministry Pharmaceutical Administration;   Italy: National Monitoring Centre for Clinical Trials - Ministry of Health;   Netherlands: The Central Committee on Research Involving Human Subjects (CCMO);   Portugal: National Pharmacy and Medicines Institute;   Spain: Spanish Agency of Medicines;   United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Hadassah Medical Organization:
Septic shock
Steroids
Hydrocortisone
Mortality
Reversal of shock
Adrenal insufficiency

Study placed in the following topic categories:
Systemic Inflammatory Response Syndrome
Sepsis
Adrenal Insufficiency
Hydrocortisone
Cortisol succinate
Shock
Shock, Septic
Hydrocortisone acetate
Epinephrine
Hypoadrenalism
Adrenal gland hypofunction
Inflammation

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Pathologic Processes
Therapeutic Uses
Infection
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009